国际化破局君实生物再掀新热潮自2012年12月成立之初,君实生物便以创新为驱动,致力于创新疗法的发现、开发和商业化。特瑞普利单抗作为君实生物的首款自主研发产品,经过数年的潜心研究与开发,于2018年12月在中国内地获批上市,成为中国首个以PD-1为靶点的国产单抗药物,标志着中国在肿瘤免疫治疗领域取得了重大突破。特瑞普利单抗作为一种人源化IgG4型单克隆抗体,通过特异性结合PD-1受体,阻断PD-1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.